Close

News

Bharat Biotech’s Covid-19 vaccine to use ViroVax’s adjuvant for longer-lasting immunity

Vaccines major Bharat Biotech on Monday announced its coronavirus disease (Covid-19) vaccine Covaxin will use adjuvant Alhydroxiquim-II to boost immune response. An adjuvant is a...

Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the...

Siegfried to Acquire Two Pharmaceutical Manufacturing Sites from Novartis in Spain

Siegfried has signed binding agreements with Novartis regarding the acquisition of two pharmaceutical manufacturing sites in Spain. With this acquisition, Siegfried will significantly enhance...

BMS Announces Update on CheckMate -915 Evaluating Opdivo Plus Yervoy Versus Opdivo in Resected High-Risk Melanoma Patients

Bristol Myers Squibb announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus...

EMA starts first rolling review of a COVID-19 vaccine in the EU

EMA’s human medicines committee (CHMP) has started the first ‘rolling review’ of a COVID-19 vaccine, which is being developed by the company AstraZeneca in...

AstraZeneca: COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency...

BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced that it has established a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read